Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a patient-centric commercial-stage biopharmaceutical company dedicated to bringing innovative cardiology products to market. Our lead product, CARDAMYST™ (etripamil), is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. We are also dedicated to the continued clinical investigation of etripamil as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR). At Milestone, everything we do is with the patient in mind. To learn more, visit
www.milestonepharma.com. Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page.
https://milestonepharmaceuticals.applytojob.com/
